Cohance Lifesciences share price today

Cohance Lifesciences Ltd's share price was ₹444.30 at the close on 30 October 2026. It has been falling for 71 weeks. That is 8.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹280 and ₹708, and at that close it sat 38% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Cohance Lifesciences Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 6 weeks in a row.

Over the last 6.6 years the share price moved +205% while the NIFTY 500 moved +212%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: lowest operating margin in 15 quarters, profit down on a year earlier for 5 quarters in a row and revenue down on a year earlier for 4 quarters in a row.

1. Lowest operating margin in 15 quarters

   Operating margin was 0.3% in the June 2026 quarter, against 20% a year earlier.

   Why: Margins fell because the higher-margin pharma CDMO business brought in less and product mix got worse.

   Next results: check whether commercial deliveries, payload execution, customer approvals and factory use lift margins, since management said margin recovery is weighted to the second half.

   From the earnings call on 5 Aug 2026.

2. Profit down on a year earlier for 5 quarters in a row

   In the June 2026 quarter profit was ₹-45 crore, -197.8% on a year earlier.

   Why: Profit fell because revenue dropped, margins shrank, and NJ Bio ran a large loss while its costs stayed high.

   From the earnings call on 5 Aug 2026.

3. Revenue down on a year earlier for 4 quarters in a row

   In the June 2026 quarter revenue was ₹422 crore, -23.1% on a year earlier.

   Why: Revenue fell because customers moved pharma CDMO shipments out of the quarter.

   Next results: check whether scheduled commercial deliveries and restocking orders bring revenue back, since management called Q1 the trough.

   From the earnings call on 5 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Cohance Lifesciences reported revenue of ₹422 crore, down 23.1% from ₹549 crore a year earlier, and a loss of ₹45.0 crore, down 197.8% from ₹46.0 crore.

Cohance Lifesciences results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Cohance Lifesciences' management discussed these results on a call held on 5 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Cohance Lifesciences closed at ₹444.30 on 30 October 2026, down 41.0% from ₹753.40 a year earlier (31 October 2025) and down 12.6% over five years. Its highest weekly close since March 2020 was ₹1,327.15 on 1 November 2024.

Cohance Lifesciences share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes.

352 weekly closes from 13 March 2020 to 30 October 2026.

30 Oct 2026: Cohance Lifesciences closed at ₹444.30, down 1.2% on the week and down 1.6% on the month. 5 Aug 2026: Cohance Lifesciences held its results call for April to June 2026. Management guided: Q2 sequential improvement, year-on-year comparability by end-H1 and year-on-year growth from H2 FY27; margin recovery weighted to H2.

Earlier

• Results for April to June 2026: Revenue down 23.1% and profit down 197.8% on a year earlier.

Not in its latest year. Cohance Lifesciences Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 4 of its last 8 reported years, so there is a history but no current dividend (as of 30 October 2026).

On the call for April to June 2026, held on 5 August 2026, Cohance Lifesciences' management guided: Q2 sequential improvement, year-on-year comparability by end-H1 and year-on-year growth from H2 FY27; margin recovery weighted to H2.

“At this point, I am almost feeling that the target is an aspiration. I am not sure that we are at a point where we can say how close we will be to it, whether we will fall short of it or whether we will exceed it.”Umang Vohra, on the call for April to June 2026

What management guided

• Operating margin expected nearer the previous year's percentage in FY27, then accelerate from FY28.
• Two recently commercialized molecules are scheduled to deliver six intermediates across Q2-Q3; customized ADC payload due Q2.
• Restocking order for one commercial molecule to provide delivery visibility across January to March 2027 and FY28.
• API Plus: 7 new API filings in FY27, 2 formulation launches in Q2 and around 10 launches across the fiscal year.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 5 August 2026.

When Cohance Lifesciences reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Q2 sequential improvement - check commercial deliveries, payload execution, customer approvals and utilization.

Cohance Lifesciences is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.

Cohance Lifesciences Ltd posted a net loss of ₹45.0 Cr in the Jun 2026 quarter. Full-year FY26 profit was ₹150 Cr. Over 7 years profit has grown 4.7% a year on average. That loss is 10.7% of the quarter's revenue. The same quarter a year earlier earned ₹46.0 Cr. 1 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Jun 2026 profit was −₹45.0 Cr, −197.8% on a year earlier. For the full year, FY26 profit was ₹150 Cr (−69.0% on the year before).

Why profit moved: revenue changed −23.1% on a year earlier and the margin moved −19.7 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −106.0% and revenue −19.2%. Profit is growing slower than sales: rising costs are taking part of the growth.

Cohance Lifesciences Ltd reported ₹422 Cr of revenue in the Jun 2026 quarter, −23.1% on the same quarter a year earlier. Over 7 years it has grown 29.2% a year on average. The last full year, FY26, came in at ₹2,269 Cr. The last four reported quarters add to ₹2,142 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹2,269 Cr, −13.0% on the year before.

Recent pace: the last four quarters grew −19.2% on average, against 29.2% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −19.7%, against +34.1% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −87.2%, against −52.3% a year (rolling over).

Cohance Lifesciences Ltd's operating margin was 0.3% in the Jun 2026 quarter, 19.7 percentage points lower than the same quarter a year ago. Across 8 years it has been between 19.0% and 46.0%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −20.1 percentage points on the year while gross margin changed −1.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 150% of Cohance Lifesciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹368 Cr of operating cash against ₹150 Cr of profit. After ₹293 Cr of spending on assets, ₹75.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 150% of profit came in as cash: the cash cycle got 83 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 7.6× depreciation over three years. The next section checks what that spending is building.

Cohance Lifesciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 263 days in FY26, up from 180 days in FY21. It spent ₹3,128 Cr on assets over the last 3 years. Customers take 110 days to pay, and stock sits for 310 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹2,269 Cr, each day of that cycle ties up about ₹6.2 Cr, so roughly ₹1,635 Cr is tied up in the business at any time.

FY26: customers took 110 days to pay and stock sat for 310 days, about 10.2 months of sales sitting as stock, for a full cycle of 263 days, longer than FY21's 180.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 310 days. Customers pay about 110 days after that. Suppliers are paid at 157 days. Together that makes the 263-day cycle.

Spending on assets: ₹3,128 Cr over the last 3 years, against ₹409 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹178 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Cohance Lifesciences Ltd's P/E is 158.0×, about the highest it has ever been. Its usual P/E (the middle reading) is 38.5×, over 6.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹2.78.

Why the multiple is where it is: over the past year earnings per share moved −75.5% while the price moved −41.0%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 5 years the price moved −2.7% a year; about −28.3% a year came from earnings growth and about +25.6 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 138% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Cohance Lifesciences Ltd's business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −19.7% in the latest quarter, against +147.9% at its best in 12 quarters, with ROCE falling at 6.0%. This is based on 8 quarters of 4 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Cohance Lifesciences Ltd earned a ROCE of 6% in FY26. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 6.6% net margin and 0.40× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 6.6% net margin × 0.40× asset turnover × 1.46× leverage (assets divided by equity) ≈ 3.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 138% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Cohance Lifesciences Ltd had ₹400 Cr of borrowings against ₹3,911 Cr of equity in FY26, so its debt is 0.10× its equity. Its operating profit is 12 times its interest bill. Over 5 years borrowings went from ₹143 Cr to ₹400 Cr. Over the last 3 of those years it spent ₹3,128 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

Part of the spending on assets is being paid for with borrowed money.

The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 138% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Promoters raised their stake in Cohance Lifesciences Ltd by 7.4 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 57.5% of the company. Foreign institutions moved −3.0 points over the same period, to 7.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Promoters: +7.4 points over 8 quarters, to 57.5%; Foreign institutions: −3.0 points over 8 quarters, to 7.7%; Domestic institutions: +1.9 points over 8 quarters, to 18.9%.

Why the owners changed: foreign institutions moved −3.0 points and domestic institutions +1.9 points over 8 quarters, while promoters moved +7.4 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company.

For Cohance Lifesciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

There is no score against its industry: Cohance Lifesciences Ltd is score temporarily unavailable, fetchAllRows(mlaSectorData.supplemental[1]): page at offset 1000 failed: canceling statement due to statement timeout for undefined.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, score temporarily unavailable, fetchAllRows(mlaSectorData.supplemental[1]): page at offset 1000 failed: canceling statement due to statement timeout.

Cohance Lifesciences is the 12th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Granules India, Shilpa Medicare and OneSource Specialty Pharma. Just below it: Syngene International, Jubilant Pharmova and Concord Biotech.

Pharma - API & CRAMS companies close in size

9. Granules India Ltd ₹22,907 crore
10. Shilpa Medicare Ltd ₹18,690 crore
11. OneSource Specialty Pharma Ltd ₹17,924 crore
12. Cohance Lifesciences Ltd ₹16,999 crore
13. Syngene International Ltd ₹16,256 crore
14. Jubilant Pharmova Ltd ₹14,716 crore
15. Concord Biotech Ltd ₹13,031 crore

All 24 Pharma - API & CRAMS companies, largest first

Companies close in size in other industries

396. International Gemological Institute Limited ₹17,189 crore · Lab Grown Diamonds
397. The Ramco Cements Ltd ₹17,005 crore · Cement
398. Cohance Lifesciences Ltd ₹16,999 crore
399. LMW Ltd ₹16,977 crore · Textile machinery
400. Sigma Advanced System Ltd ₹16,915 crore · Aerospace & Defence - Equipments

Sector Alpha, written by code from the published numbers. Data as of 30 October 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.